Molecular mechanisms of oxidative stress in asthma

C Michaeloudes, H Abubakar-Waziri, R Lakhdar… - Molecular aspects of …, 2022 - Elsevier
The lungs are exposed to reactive oxygen species oxygen (ROS) produced as a result of
inhalation of oxygen, as well as smoke and other air pollutants. Cell metabolism and the …

The extracellular matrix in ischemic and nonischemic heart failure

NG Frangogiannis - Circulation research, 2019 - Am Heart Assoc
The ECM (extracellular matrix) network plays a crucial role in cardiac homeostasis, not only
by providing structural support, but also by facilitating force transmission, and by transducing …

Periosteum contains skeletal stem cells with high bone regenerative potential controlled by Periostin

O Duchamp de Lageneste, A Julien… - Nature …, 2018 - nature.com
Bone regeneration relies on the activation of skeletal stem cells (SSCs) that still remain
poorly characterized. Here, we show that periosteum contains SSCs with high bone …

Type 2 inflammation in asthma—present in most, absent in many

JV Fahy - Nature Reviews Immunology, 2015 - nature.com
Asthma is one of the most common chronic immunological diseases in humans, affecting
people from childhood to old age. Progress in treating asthma has been relatively slow and …

Revisiting T ype 2‐high and T ype 2‐low airway inflammation in asthma: current knowledge and therapeutic implications

D Robinson, M Humbert, R Buhl… - Clinical & …, 2017 - Wiley Online Library
Asthma is a complex respiratory disorder characterized by marked heterogeneity in
individual patient disease triggers and response to therapy. Several asthma phenotypes …

Immunopathogenesis of chronic rhinosinusitis and nasal polyposis

RP Schleimer - Annual Review of Pathology: Mechanisms of …, 2017 - annualreviews.org
Chronic rhinosinusitis (CRS) is a troublesome, chronic inflammatory disease that affects
over 10% of the adult population, causing decreased quality of life, lost productivity, and lost …

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo …

NA Hanania, P Korenblat, KR Chapman… - The Lancet …, 2016 - thelancet.com
Background In phase 2 trials, lebrikizumab, an anti-interleukin-13 monoclonal antibody,
reduced exacerbation rates and improved FEV 1 in patients with uncontrolled asthma …

The airway epithelium in asthma

BN Lambrecht, H Hammad - Nature medicine, 2012 - nature.com
Asthma is a T lymphocyte–controlled disease of the airway wall caused by inflammation,
overproduction of mucus and airway wall remodeling leading to bronchial hyperreactivity …

Lebrikizumab treatment in adults with asthma

J Corren, RF Lemanske Jr, NA Hanania… - … England Journal of …, 2011 - Mass Medical Soc
Background Many patients with asthma have uncontrolled disease despite treatment with
inhaled glucocorticoids. One potential cause of the variability in response to treatment is …

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

NA Hanania, M Noonan, J Corren, P Korenblat… - Thorax, 2015 - thorax.bmj.com
Introduction In a subset of patients with asthma, standard-of-care treatment does not achieve
disease control, highlighting the need for novel therapeutic approaches. Lebrikizumab is a …